Amicus Therapeutics (FOLD) : Venbio Select Advisor reduced its stake in Amicus Therapeutics by 0.24% during the most recent quarter end. The investment management company now holds a total of 3,689,857 shares of Amicus Therapeutics which is valued at $34,315,670 after selling 8,808 shares in Amicus Therapeutics , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Amicus Therapeutics makes up approximately 6.42% of Venbio Select Advisor’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in FOLD in the latest quarter, The investment management firm added 45,280 additional shares and now holds a total of 505,081 shares of Amicus Therapeutics which is valued at $4,697,253. Amicus Therapeutics makes up approx 0.01% of Schwab Charles Investment Management Inc’s portfolio. Sg Americas Securities added FOLD to its portfolio by purchasing 20,395 company shares during the most recent quarter which is valued at $151,535.New York State Common Retirement Fund reduced its stake in FOLD by selling 8,228 shares or 5.48% in the most recent quarter. The Hedge Fund company now holds 141,800 shares of FOLD which is valued at $1,053,574.Blackrock Japan Ltd boosted its stake in FOLD in the latest quarter, The investment management firm added 239 additional shares and now holds a total of 631 shares of Amicus Therapeutics which is valued at $4,688.
Amicus Therapeutics closed down -0.12 points or -1.35% at $8.75 with 21,38,022 shares getting traded on Monday. Post opening the session at $8.9, the shares hit an intraday low of $8.58 and an intraday high of $8.96 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Amicus Therapeutics reported $-0.33 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Nov 7, 2016. Analyst had a consensus of $-0.31. The company had revenue of $2.10 million for the quarter, compared to analysts expectations of $2.16 million.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.